Dermatopathology Diagnostic Solutions

We offer over 45 cornerstone and novel dermatopathology ready-to-use reagents, including key IHC and FITC antibodies, which aid in melanoma diagnosis, basal cell carcinoma diagnosis, squamous cell carcinoma diagnosis, and other dermatological malignancies.

Our robust menu of tools aid in Dermatopathology diagnostics and treatment. Our portfolio of immunohistochemistry detection products delivers the high sensitivity and specificity you need from your assays. Our antibodies are ready to use on the fully- automated VENTANA BenchMark IHC/ISH staining platforms, reducing the time-to-result and resources required with manual or semi-automated solutions.

SOX-10 (SP267) Rabbit Monoclonal Primary Antibody

SOX-10 (SP267) Rabbit Monoclonal Primary Antibody is intended for laboratory use in the detection of the SOX-10 protein in formalin-fixed, paraffin-embedded tissue stained on BenchMark immunohistochemical (IHC/ISH) automated slide stainers. SOX-10 is a nuclear transcription factory that participates in neural crest development and in the specification and differentiation of cells of melanocytic lineage.1

 

> View in product catalog

CONFIRM MART-1 / melan A (A103) Mouse Monoclonal Primary Antibody

CONFIRM MART-1/ melan A (A103) Mouse Monoclonal Primary Antibody is a mouse monoclonal antibody (IgG1) directed against melan A. Positive staining may aid in the classification of melanoma.2,3

 

> View in product catalog

References

1. Kelsch RN. Sorting out SOX10 functions in neural crest development. BioEssays. 2006; 28:788

2. Chen YT, Stockert E, Jungbluth A, Tsang S, Coplan KA, Scanlan MJ, Old LJ. Serological analysis of Melan-A (MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas. Proc Natl Acad Sci U S A 1996 Jun 11;93(12):5915-9.

3. Jager e, Ringhoffer M, Karbach J, Arand M, Oesch F, Knuth A. Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer. 1996 May 16;66(4):470-6.